Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2019
Event: Entry into Material Definitive Agreements and Unregistered Sales of Equity Securities.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. Key metrics from the transaction include:
- Shares Sold: 460,545 shares of Common Stock.
- Purchase Price: $9.00 per share.
- Total Proceeds: $4,144,900.
- Investor Participation: Five accredited investors, including the CEO (11,100 shares) and CFO (5,000 shares).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific offering.
Material Changes
The primary material change is the increase in equity capital and outstanding share count resulting from the private placement. The company entered into Securities Purchase Agreements to sell unregistered shares in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the offering and the participation of key executives (CEO and CFO).
Contingencies: The Company agreed to file a registration statement with the SEC within 30 days after the effectiveness of a registration statement for the resale of securities issued to certain investors.
Risks: The filing does not explicitly detail new risks, though the transaction involves unregistered securities sold to accredited investors only.
Investor Verification Checklist
- Verify the final number of shares issued and the exact closing date of the transaction.
- Confirm the filing of the subsequent registration statement for resale of the shares as agreed.
- Review the company's latest 10-K or 10-Q to assess how these proceeds impact overall liquidity and cash runway.
- Check for any dilution impact on existing shareholders given the issuance of 460,545 new shares.